Opus Point Partners Management LLC

Search
⚲

Opus Point Partners Management LLC ✚
CRD #	161996
SEC #	802-76334
CIK #	0001503454, 0001600175
AUM
Employees
Phone	212-554-4504
Address	2 Gansevoort Street New York, NY 10014
Source	[IAPD] [EDGAR] [Website]

Total AUM ($) Copy

CIK	Period
0001503454 0001600175	2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31

Sector	Form 13F Holdings	Value ($M)
	Mettler Toledo International INC/	2.3
	Bristol Myers Squibb Co	1.7
	Illumina Inc	1.4
	Vertex Pharmaceuticals Inc / Ma	1.4
	ISIS Pharmaceuticals Inc	1.2
	Alnylam Pharmaceuticals Inc	1.1
	Qiagen NV	1.0
	Coronado Biosciences Inc	0.9
	Proqr Therapeutics NV	0.8
	Incyte Corp	0.8
	Regeneron Pharmaceuticals Inc	0.7
	BioMarin Pharmaceutical Inc	0.7
	Ascendis Pharma A/S	0.6
	Uniqure NV	0.6
	CRISPR Therapeutics AG	0.5
	Amarin Corp PLC UK	0.5
	Boundless Bio Inc	0.5
	Biohaven Ltd	0.5













Prev \| Page 1 \| Next

Type	Form D Funds	Date	Sold	AUM
HF	Opus Point Biotechnology Fund LLC	2015-03-31		7.4 M
HF	Opus Point Healthcare Value Fund LP	[2013-05-14]		8.2 M
	Filed 2008-11-25 (D) · Exemption 506 · Minimum $2,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Over $100,000,000
HF	Opus Point Healthcare Innovations Fund LP	[2012-04-02]	89.8 M	77.8 M
	Filed 2020-05-20 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $2,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF	Opus Point Healthcare Innovations Offshore Fund Limited	[2012-04-02]	33.1 M	33.2 M
	Filed 2020-07-21 (D/A) · Exemption 506(b) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets No Aggregate Net Asset Value
HF	Opus Point Healthcare Low Net Fund LP	[2012-04-02]		7.0 M
	Filed 2008-10-14 (D) · Exemption 506 · Minimum $2,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Over $100,000,000

AUM Breakdown	Accounts	AUM ($)
By Client Type
(a) Individuals (other than high net worth individuals)	0	0.0
(b) Individuals (high net worth individuals)	0	0.0
(c) Banking or thrift institutions	0	0.0
(d) Investment companies	0	0.0
(e) Business development companies	0	0.0
(f) Pooled investment vehicles	0	0.0
(g) Pension and profit sharing plans	0	0.0
(h) Charitable organizations	0	0.0
(i) State or municipal government entities	0	0.0
(j) Other investment advisers	0	0.0
(k) Insurance companies	0	0.0
(l) Sovereign wealth funds and foreign official institutions	0	0.0
(m) Corporations or other businesses not listed above	0	0.0
(n) Other	0	0.0
Total	0	0.0
By Discretionary
Discretionary	0	0.0
Non-Discretionary	0	0.0
Total	0	0.0
By Non-United States Persons
Non-United States Persons		0.0
United States Persons		0.0
Total	0	0.0

Form D Directors	Role	# Filings	# Firms
Wade Kenny	Director	86	31
Dawn Cummings	Director	13	7
Michael Weiss	Director, Executive Officer	66	5
Lindsay Rosenwald	Executive Officer	25	2
Lindsay Rosenwald MD	Director	6	2
Opus Point Healthcare Fund GP LLC	Promoter	2	1
NA Opus Point Healthcare Fund GP LLC	Promoter	1	1
Kevin Philips	Director	1	1

Form 13D/13G Filer	Form 13D/13G Subject	Filed
Opus Point Partners LLC	Anthera Pharmaceuticals Inc	[2012-08-27]
Opus Point Partners LLC	Manhattan Pharmaceuticals Inc	[2012-01-10]

Firm Profile (Form ADV)
Fund Types	Hedge Fund

Form 3/4/5 Subject	2011 - 2026
Opus Point Healthcare Innovations Offshore Fund Ltd
FBIO Acquisition Inc
Coronado Biosciences Inc
Opus Point Partners LLC
National Holdings Corp
Weiss Michael S
Rosenwald Lindsay A MD
TG Therapeutics Inc

Assets, Funds, Holdings